期刊
CLINICA CHIMICA ACTA
卷 483, 期 -, 页码 64-68出版社
ELSEVIER
DOI: 10.1016/j.cca.2018.04.024
关键词
HOXA13; Solid tumors; Prognosis; Meta-analysis; Biomarker
资金
- National Natural Science Foundation of China [81402430]
- Collaborative Innovation Project of Guangzhou Education Bureau the Guangzhou Science Technology and Innovation Commission [1201620011, 201604020001, 201704020193]
- Science and Technology Planning Project of Guangdong Province [2017B030314108]
Purpose: The prognostic value of homeobox (HOX) A13 (HOXA13) in cancer remains uncertain due to limitations of sample size and discrete outcome in previous studies. We performed this meta-analysis to explore the prognostic effect of HOXA13 in patients with solid tumors. Methods: PubMed, Embase, and Web of Science were searched to identify eligible studies. Hazard ratios (HR) with 95% confidence interval (95%CI) and clinicopathological factors were extracted. Subgroup analysis according to cancer type, sample size and analysis method were also performed. Results: A total of 844 patients with solid tumor from 9 eligible studies were incorporated in the meta-analysis. We found that high HOXA13 expression level was significantly associated with poor overall survival (OS) in human cancer (HR = 2.23; 95%CI: 1.74-2.85), and significantly related to poorer histological grade (odds ratio (OR) = 2.03, 95%CI: 1.40-2.96), positive lymph node metastasis (OR = 1.96, 95%CI: 1.26-3.02) and more advanced tumor node metastasis (TNM) stage (OR = 3.92, 95%CI: 2.46-6.22). Conclusion: Our meta-analysis suggests that HOXA13 might be a valuable biomarker of poor prognosis and a potential therapeutic target for human solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据